{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:23:09Z","timestamp":1792120989949,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K24CA121990-02"],"award-info":[{"award-number":["5K24CA121990-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.eururo.2012.10.007","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T15:50:08Z","timestamp":1353685808000},"page":"309-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["New and Emerging Therapies for Bone Metastases in Genitourinary Cancers"],"prefix":"10.1016","volume":"63","author":[{"given":"Philip J.","family":"Saylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Pienta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.10.007_bib0005","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1200\/JCO.2006.09.2940","article-title":"Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies","volume":"25","author":"Lecouvet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0015","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.10.007_bib0020","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.10.007_bib0025","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2012.10.007_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.10.007_bib0040","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.10.007_bib0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.10.007_bib0050","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0055","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2012.10.007_bib0065","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1016\/S0021-9258(18)67143-1","article-title":"Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose","volume":"261","author":"Hauschka","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eururo.2012.10.007_bib0070","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1084\/jem.173.5.1291","article-title":"Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells","volume":"173","author":"Kodama","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.eururo.2012.10.007_bib0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2012.10.007_bib0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2012.10.007_bib0085","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.10.007_bib0090","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0095","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.10.007_bib0105","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","article-title":"Bone resorption predicts for skeletal complications in metastatic bone disease","volume":"89","author":"Brown","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2012.10.007_bib0110","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","article-title":"Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer","volume":"21","author":"Rajpar","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2012.10.007_bib0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2012.10.007_bib0125","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.189.7.1025","article-title":"TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation","volume":"189","author":"Bachmann","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.eururo.2012.10.007_bib0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eururo.2012.10.007_bib0135","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.10.007_bib0140","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0145","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2009.10.003","article-title":"Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain","volume":"40","author":"Paes","year":"2010","journal-title":"Semin Nucl Med"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2012.10.007_bib0155","article-title":"Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract]","volume":"30","author":"Parker","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0160","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.10.007_bib0405","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2012.10.007_bib0170","article-title":"Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA) [abstract]","volume":"30","author":"Sartor","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0175","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0180","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.10.007_bib0185","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer\u2014results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.10.007_bib0190","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0195","unstructured":"Wirth M, Tammela T, Debruyne F, et al. Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients. A randomised, open label, multicenter study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). A report of the ZEUS study [abstract 184]. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; February 14\u201316, 2008; San Francisco, CA, USA."},{"key":"10.1016\/j.eururo.2012.10.007_bib0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis\u2013free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2011","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.eururo.2012.10.007_bib0205","article-title":"Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics [abstract]","volume":"30","author":"Saad","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0210","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0215","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.10.007_bib0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.10.007_bib0225","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0230","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0235","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":"Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2012.10.007_bib0240","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","article-title":"Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2012.10.007_bib0245","article-title":"Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA) [abstract]","volume":"30","author":"Parker","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0250","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y","article-title":"The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group","volume":"50","author":"Tong","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.10.007_bib0255","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0885-3924(01)00359-1","article-title":"Single fraction external beam radiation therapy in the treatment of localized metastatic bone pain. A review","volume":"22","author":"Jeremic","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.eururo.2012.10.007_bib0260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2009.11.005","article-title":"SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer","volume":"36","author":"Saad","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2012.10.007_bib0265","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/annonc\/mdm086","article-title":"The role of Src in prostate cancer","volume":"18","author":"Fizazi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0270","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.10.007_bib0275","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.10.007_bib0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":"Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.10.007_bib0285","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"Suppl","key":"10.1016\/j.eururo.2012.10.007_bib0290","article-title":"Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract]","volume":"29","author":"Hussain","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.eururo.2012.10.007_bib0295","article-title":"Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease [abstract]","volume":"29","author":"Smith","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0300","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2012.10.007_bib0305","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive castration-resistant prostate cancer (mCRPC) [abstract]","volume":"29","author":"Michaelson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0310","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1078-0432.CCR-09-1365","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors","volume":"16","author":"Gordon","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2012.10.007_bib0315","article-title":"A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC) [abstract]","volume":"30","author":"Ryan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0320","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0325","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.eururo.2012.10.007_bib0330","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2012.10.007_bib0335","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2012.10.007_bib0340","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2012.10.007_bib0345","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2012.10.007_bib0350","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eururo.2012.10.007_bib0355","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0360","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2012.10.007_bib0365","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0370","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.14219\/jada.archive.2008.0110","article-title":"Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs","volume":"139","author":"Edwards","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.eururo.2012.10.007_bib0375","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2012.10.007_bib0380","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2012.10.007_bib0385","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.eururo.2012.10.007_bib0390","unstructured":"Zometa [package insert]. Basel, Switzerland: Novartis International AG; 2009."},{"key":"10.1016\/j.eururo.2012.10.007_bib0395","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.10.007_bib0400","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812012262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812012262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:02:58Z","timestamp":1759582978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812012262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0302283812012262"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.10.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and Emerging Therapies for Bone Metastases in Genitourinary Cancers","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2012.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}